- Home
- EXAS vs CZR Comparison
EXAS vs CZR Comparison
Compare EXAS & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXAS | CZR |
|---|---|---|
| Founded | 1995 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 4.7B |
| IPO Year | N/A | 1989 |
Fundamental Metrics
Financial Performance| Metric | EXAS | CZR |
|---|---|---|
| Price | $101.76 | $23.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 15 |
| Target Price | ★ $80.25 | $34.40 |
| AVG Volume (30 Days) | 3.3M | ★ 5.4M |
| Earning Date | 02-18-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,082,033,000.00 | ★ $11,369,000,000.00 |
| Revenue This Year | $19.40 | $3.10 |
| Revenue Next Year | $13.51 | $2.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.47 | 0.87 |
| 52 Week Low | $38.81 | $18.25 |
| 52 Week High | $102.66 | $40.00 |
Technical Indicators
Market Signals| Indicator | EXAS | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 82.18 | 52.45 |
| Support Level | $101.51 | $23.12 |
| Resistance Level | $102.05 | $24.81 |
| Average True Range (ATR) | 0.36 | 0.71 |
| MACD | -1.10 | -0.16 |
| Stochastic Oscillator | 61.69 | 31.91 |
Price Performance
Historical ComparisonAbout EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.